Drugs / Cabiralizumab
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials · 1 met primary | ||||||
| Phase 1 | NCT03502330 | Jun 2018 → Jan 2022 | melanoma, non-small cell lung carcinoma, renal cell carcinoma | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03335540 | May 2018 → Mar 2021 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | Met primary |
| Phase 1 | NCT03431948 | Mar 2018 → Feb 2020 | cancer | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT03158272 | May 2017 → Oct 2019 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02526017 | Sep 2015 → Nov 2019 | head and neck cancer, malignant glioma, malignant pancreatic neoplasm, non-small cell lung carcinoma +2 | Five Prime Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01962337 | Oct 2013 → Apr 2016 | rheumatoid arthritis | Five Prime Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04331067 | Nov 2020 → Mar 2023 | triple-negative breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT02471716 | Jun 2015 → Apr 2020 | tenosynovial giant cell tumor, diffuse type | Five Prime Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03697564 | Oct 2019 → Apr 2023 | pancreatic exocrine neoplasm | Hitendra Patel | Completed | No outcome recorded |
| Phase 2 | NCT04050462 | Sep 2019 → Jan 2025 | hepatocellular carcinoma | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03768531 | Jun 2019 → Jan 2023 | biliary tract cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03927105 | Apr → Nov 2019 | peripheral T-cell lymphoma, not otherwise specified | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03599362 | Jul 2018 → Jun 2020 | malignant pancreatic neoplasm | NYU Langone Health | Terminated | No outcome recorded |
| Phase 2 | NCT03336216 | Dec 2017 → Jun 2023 | pancreatic neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-05-16 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018 bms.com ↗
Pharmacodynamics and genomic profiling of patients treated with cabiralizumab plus nivolumab provide evidence of on-target tumor immune modulations and support future clinical applications |
| 2017-11-09 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors bms.com ↗
In a cohort of heavily pre-treated patients with advanced pancreatic cancer (n=31 evaluable patients), a patient population that is generally insensitive to immunotherapy, durable clinical benefit was observed in five patients (16%), including confirmed objective responses in three patients with microsatellite-stable (MSS) disease (objective response rate 10%). |
All press releases naming this drug 3 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cabiralizumab | “Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks.” NCT03768531 ↗ |
| Known as | BMS-986227 | “A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies” NCT03158272 ↗1“Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine” NCT03697564 ↗ |
| Known as | FPA008 | “A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies” NCT03158272 ↗ |
| Action | Inhibit | “an Anti-CSF1 Receptor Antibody” NCT02471716 ↗ |
| Modality | Monoclonal antibody | “a CSF1-R monoclonal antibody” NCT02471716 ↗ |
| Route | Intravenous | “IV infusion” NCT02471716 ↗ |
| Target | CSF1R | “CSF1R inhibitor cabiralizumab” PMID 34140403 ↗ Jun 2021 |